Spinal cord pathology in a Dravet Syndrome mouse model
Juan F. Antinao DiaziD, Ellie M. ChilcottiD, Anna KeeganiD, Stéphanie SchorgeiD, Simon N. WaddingtoniD, Rajvinder KardaiD
Abstract
SummaryO_ST_ABSObjectivesC_ST_ABSDravet syndrome is a severe epileptic encephalopathy that begins in early childhood. More than 80% of patients with Dravet syndrome exhibit a haploinsufficiency in SCN1A, which encodes the voltage-gated sodium ion channel NaV1.1. The epilepsy is believed be caused by specific deficit of SCN1A in inhibitory interneurons of the hippocampus. However, the aetiology of other symptoms including gait disturbances, ataxia, cardiac issues and dysautonomia is less clear. MethodsIn an Scn1a knock-out (Scn1a-/-) mouse model which recapitulates clinical phenotypes, we assessed NaV1.1 and neuroinflammation throughout the central nervous system. ResultsConsistent with current understanding, wild-type expression of NaV1.1 transcript and protein were absent in knock-out mice in the prefrontal cortex, striatum, hippocampus, thalamus, and cerebellum. Increased GFAP was detected in the brain only in the hippocampus. Transcript and protein were detected in wild-type cervical, thoracic and lumbar spinal cord but not in knock-out mice. Unexpectedly, GFAP was increased in all three spinal regions. Therefore, we proceeded to perform transcriptomic analysis of cortex, hippocampus and spinal cord. Pathways associated with monooxygenase activity, fatty acid ligases and lactate transporters were highly dysregulated in the spinal cord. ConclusionThe existence and relevance of pathology of the spinal cord in Dravet syndrome has received scant attention. Our findings are consistent with some systemic symptoms of Dravet syndrome, with the benefits of treatments which may modulate the astrocyte-neuron lactate shuttle such as Stiripentol and ketogenic dietary regimes, and with the efficacy of intrathecal delivery of therapeutics. Key PointsO_LIDecrease of endogenous Scn1a and NaV1.1 expression in Scn1a-/- mice has a widespread impact on the gene expression profile in the spinal cord. C_LIO_LIIncreased GFAP expression observed in the spinal cord of Scn1a-/- mice. C_LIO_LIDifferentially expressed genes related to monooxygenase activity, fatty acid ligases and lactate transporters in cervical spinal cord of Scn1a-/- mice. C_LI
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Medial septum parvalbumin-expressing inhibitory neurons are impaired in a mouse model of Dravet Syndrome
Limei Zhu, Yiannos Demetriou, … Joanna Mattis·EpilepsiaPeer-reviewed·Jul 7, 2025
- Synaptic and intrinsic mechanisms impair reticular thalamus and thalamocortical neuron function in a Dravet syndrome mouse model
Carleigh Studtmann, Marek Ladislav, … Sharon A. Swanger·bioRxiv·Sep 3, 2021
- Inhibitory synaptic transmission is impaired at higher extracellular Ca2+ concentrations in Scn1a+/- mouse model of Dravet syndrome
Kouya Uchino, Hiroyuki Kawano, … Shinichi Hirose·Scientific ReportsPeer-reviewed·May 20, 2021
- Developmentally-regulated impairment of parvalbumin interneuron synaptic transmission in an experimental model of Dravet syndrome
Keisuke Kaneko, Christopher Brian Currin, … Ethan M. Goldberg·Cell ReportsPeer-reviewed·Mar 1, 2022
- Exogenous Nav1.1 activity in excitatory and inhibitory neurons reverts Dravet syndrome comorbidities when delivered post-symptom onset in mice with Dravet
Saja Fadila, Bertrand Beucher, … Moran Rubinstein·bioRxiv·Jun 10, 2022
- Astrocyte Ca2+ Signaling is Facilitated in an Scn1a+/- Mouse Model of Dravet Syndrome
Kouya Uchino, Yasuyoshi Tanaka, … Shinichi Hirose·bioRxiv·May 18, 2021